Results 211 to 220 of about 2,446,622 (333)

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

What are data spaces? Systematic survey and future outlook. [PDF]

Data Brief
Bacco M, Kocian A, Chessa S, Crivello A, Barsocchi P.   +4 more
europepmc   +1 more source

Systematic Survey of Vibrio spp. and Salmonella spp. in Bivalve Shellfish in Apulia Region (Italy): Prevalence and Antimicrobial Resistance. [PDF]

Microorganisms, 2023
Mancini ME, Alessiani A, Donatiello A, Didonna A, D'Attoli L, Faleo S, Occhiochiuso G, Carella F, Di Taranto P, Pace L, Rondinone V, Damato AM, Coppola R, Pedarra C, Goffredo E.   +14 more
europepmc   +1 more source

Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews [PDF]

, 2009
Fujian Song, Yoon K. Loke, Tanya Walsh, Anne‐Marie Glenny, Alison Eastwood, Doug Altman   +5 more
openalex   +1 more source

National and subnational survey on diabetes burden and quality of care index in Iran: a systematic analysis of the global burden of disease study 1990–2019

, 2022
Seyedeh Farzaneh Mousavi, Maryam Peimani, Sahar Saeedi Moghaddam, Ozra Tabatabaei‐Malazy, Erfan Ghasemi, Parnian Shobeiri, Negar Rezaei, Ensieh Nasli‐Esfahani, Bagher Larijani   +8 more
openalex   +2 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Compatibility of family and clinical–scientific career for German gynecologists in different workplaces: a sub-analysis of the systematic trinational FARBEN survey [PDF]

Niklas Amann, Maggie Banys‐Paluchowski, Claudia Becker, Philipp Foessleitner, Martin C. Göpfert, Rama Kiblawi, Nora Kießling, Amanda Klee, Natalia Krawczyk, Laura Dussan Molinos, Gert Naumann, Achim Rody, Henning Schäffler, Lina Judit Schiestl, Barbara Schmalfeldt, Solveig Simowitsch, Martin Weiss, Nikolas Tauber   +17 more
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

HARNet in deep learning approach-a systematic survey. [PDF]

Sci Rep
Kumar NS, Deepika G, Goutham V, Buvaneswari B, Reddy RVK, Angadi S, Dhanamjayulu C, Chinthaginjala R, Mohammad F, Khan B.   +9 more
europepmc   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source